A
CLDX icon

AlphaQuest’s Celldex Therapeutics CLDX Stock Holding History

AlphaQuest’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,018
Closed -$218K – 410
2025
Q4 		$218K Buy
8,018
+4,316
+117% +$114K 0.01% 1400
2025
Q3 		$95.8K Sell
3,702
-9,254
-71% -$214K 0.01% 1745
2025
Q2 		$264K Buy
12,956
+844
+7% +$16.4K 0.03% 965
2025
Q1 		$220K Buy
12,112
+7,825
+183% +$175K 0.02% 936
2024
Q4 		$108K Buy
4,287
+2,705
+171% +$73.5K 0.01% 1069
2024
Q3 		$53.8K Sell
1,582
-5,801
-79% -$221K ﹤0.01% 1398
2024
Q2 		$273K Buy
7,383
+6,879
+1,365% +$260K 0.04% 663
2024
Q1 		$21.2K Buy
+504
New +$20.7K ﹤0.01% 1029

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return